CloudMile Collaborates with Google Cloud to Launch Agentic Work Transformation (AWT) Experience Center in Malaysia

KUALA LUMPUR, Malaysia, June 11, 2026 /PRNewswire/ -- CloudMile, a leading cloud and AI company in Asia, announced on June 10 the opening of its Agentic Work Transformation (AWT) Experience Center, located within the CloudMile Malaysia Center of Excellence (COE). Launched in collaboration with Google Cloud, this new facility is designed to serve as an "Always On" innovation hub, empowering businesses across Southeast Asia to experience the future of AI-driven productivity firsthand.

The new AWT Experience Center moves beyond traditional presentations by offering highly interactive, "hands-on-keyboard" demonstration zones. Centered on Gemini Enterprise and fully equipped with high-performance Google Chromebooks, the center allows decision-makers to test drive intelligent, AI-powered workflows. The experience is tailored to resonate with the region's diverse business landscape, featuring vertical-specific storytelling and use cases specifically designed for industries such as Financial Services (FSI), Manufacturing, and Retail.

"Our new Agentic Work Transformation Experience Center is a testament to our commitment to driving practical AI innovation in Malaysia and across Southeast Asia," said Jeremy Heng, Chief Commercial Officer of CloudMile. "By partnering with Google Cloud, we are moving beyond theoretical AI discussions and offering businesses a tangible environment to explore Gemini Enterprise in action. This center empowers organizations to see exactly how AI agents can revolutionize their daily operations, streamline their workflows, and accelerate their digital transformation journeys."

"At CloudMile, we aren't just deploying AI, we are architecting the future of human-machine synergy. By embedding Google Cloud's agentic capabilities into the heart of our Malaysia Centre of Excellence (CoE), we are moving beyond simple automation into a realm of intelligent & prescience orchestration. This setup allows businesses to transition from 'task-based' workflows to an Agentic Workplace, where AI doesn't just assist, it anticipates, reasons, and executes. Our CoE is the launchpad for Malaysian enterprises to reclaim their most valuable asset: the time to innovate," said Lester Leong, Country Manager of CloudMile Malaysia.

The launch represents a deepening of CloudMile's relationship with Google Cloud. Through investments in hardware, creative assets, and strategic outreach, CloudMile is working collaboratively with Google Cloud to help democratize access to advanced AI tools for businesses of all sizes—from agile startups to traditional corporate enterprises.

"To thrive in tomorrow's economy, businesses must transition from digital-first to AI-first," said Hana Raja, Country Manager, Google Cloud Malaysia. "CloudMile's local expertise combined with cutting-edge Google Cloud AI technology will provide Malaysian enterprises with dedicated resources to help make Agentic Work Transformation accessible and actionable, and help them confidently embrace an AI-first future."

As part of the customer journey, visitors to the Malaysia COE will be guided through a comprehensive physical demonstration flow, from initial data integration showcases to fully automated AI agent workflows. Businesses interested in exploring how Agentic Work Transformation can elevate their operations are invited to book a dedicated discovery and hands-on session at the CloudMile Malaysia COE.

About CloudMile

CloudMile is a leading AI and cloud technology company in Asia, focused on helping enterprises accelerate their digital transformation. As a Google Cloud Premier Partner, CloudMile leverages machine learning and big data analysis to deliver cutting-edge solutions that drive business growth and operational efficiency.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

CloudMile Collaborates with Google Cloud to Launch Agentic Work Transformation (AWT) Experience Center in Malaysia

In a breakthrough clinical trial undertaken by Australian biotechnology company Marinova, a unique seaweed extract has been shown to relieve the symptoms of benign prostatic hyperplasia (BPH).

HOBART, Australia, July 27, 2026 /PRNewswire/ -- A randomised, double-blind, placebo-controlled clinical trial evaluated the effects of fucoidan, a naturally occurring compound found in brown seaweed, on men with BPH (prostate enlargement).

BPH is a common health issue for men across the globe. Worldwide estimates place prevalence at 50-60% of men in their 60s, increasing to 90% of men in their 80s. While it is typically not life-threatening, urinary symptoms – including difficulty passing urine, a weak stream and an increase in the frequency of urination – often result in a significant reduction in quality-of-life.

Speaking of the rationale behind the study, lead researcher Dr Barbara Wimmer said, "To date, very few natural compounds have been clinically studied and shown to support prostate health effectively. The documented bioactivities of fucoidan led us to embark on this groundbreaking trial."

In the 90-day study overseen by clinicians, 88 men aged between 45 and 80 years with moderate BPH received either a daily fucoidan supplement or a placebo.

Key findings
Compared to the placebo, participants taking the high purity fucoidan supplement showed:

• Clinically significant improvements in overall BPH symptoms
• A more than nine-fold improvement in voiding symptoms (encompassing the symptoms of emptying, intermittency, weak stream and straining)
• A two-fold improvement in storage symptoms (encompassing the symptoms of frequency, urgency and nocturia)
• A significant improvement in quality-of-life due to urinary symptoms

Watch the clinical trial overview and learn more about the findings.

The study utilised the widely recognised International Prostate Symptom Score (IPSS) to assess changes in BPH symptoms.

Dr Wimmer explained, "Importantly, the trial results were clinically significant and the fucoidan was shown to be safe throughout the study period. We expect these findings will result in the commercialisation of high purity fucoidan to help relieve the symptoms of benign prostatic hyperplasia."

The study was published in the journal Research and Reports in Urology.  

About Marinova          

Marinova is an Australian biotechnology company specialising in the research, development and manufacture of high purity fucoidans for inclusion in nutritional, medical device, skincare and pharmaceutical applications. 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Seaweed extract shown to relieve prostate symptoms